Jaime Gonzalez-Lopez

Dr. Jaime Gonzalez-Lopez


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2016 in Gut
Verified
Journal Article
Open access
PDF file
JIJulio Iglesias-Garcia
Julio Iglesias-Garcia
WHWei Huang
Wei Huang
Peter SzatmaryPeter Szatmary
Peter Szatmary
IBIria Baston-Rey
Iria Baston-Rey
JGJaime Gonzalez-Lopez
Jaime Gonzalez-Lopez
NGNIHR Pancreas Biomedical Research Unit Patient Advisory Group
NIHR Pancreas Biomedical Research Unit Patient Advisory Group
Objective: The benefits of pancreatic enzyme replacement therapy (PERT) in chronic pancreatitis (CP) are inadequately defined. We have undertaken a systematic review and meta-analysis of randomised controlled trials of PERT to determine the efficacy of PERT in exocrine pancreatic insufficiency (EPI) from CP. Design: Major databases were searched from 1966 to 2015 inclusive. The primary outcome was coefficient of fat absorption (CFA). Effects of PERT versus baseline and versus placebo, and of different doses, formulations and schedules were determined. Results: A total of 17 studies (511 patients with CP) were included and assessed qualitatively (Jadad score). Quantitative data were synthesised from 14 studies. PERT improved CFA compared with baseline (83.7±6.0 vs 63.1±15.0, p<0.00001; I2=89%) and placebo (83.2±5.5 vs 67.4±7.0, p=0.0001; I2=86%). PERT improved coefficient of nitrogen absorption, reduced faecal fat excretion, faecal nitrogen excretion, faecal weight and abdominal pain, without significant adverse events. Follow-up studies demonstrated that PERT increased serum nutritional parameters, improved GI symptoms and quality of life without significant adverse events. High-dose or enteric-coated enzymes showed a trend to greater effectiveness than low-dose or non-coated comparisons, respectively. Subgroup, sensitive and meta-regression analyses revealed that sample size, CP diagnostic criteria, study design and enzyme dose contributed to heterogeneity; data on health inequalities were lacking. Conclusions: PERT is indicated to correct EPI and malnutrition in CP and may be improved by higher doses, enteric coating, administration during food and acid suppression. Further studies are required to determine optimal regimens, the impact of health inequalities and long-term effects on nutrition.

12 September 2008 in Langmuir
Verified
Journal Article
Closed access
JGJaime Gonzalez-Lopez
Jaime Gonzalez-Lopez
Carmen Alvarez-LorenzoCarmen Alvarez-Lorenzo
Carmen Alvarez-Lorenzo
pablo Taboadapablo Taboada
pablo Taboada
ASAlejandro Sosnik
Alejandro Sosnik
ISIsabel Sandez-Macho
Isabel Sandez-Macho
ACAngel Concheiro
Angel Concheiro

1 May 2007 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
Carmen Alvarez-LorenzoCarmen Alvarez-Lorenzo
Carmen Alvarez-Lorenzo
JGJaime Gonzalez-Lopez
Jaime Gonzalez-Lopez
MFMarta Fernandez-Tarrio
Marta Fernandez-Tarrio
ISIsabel Sandez-Macho
Isabel Sandez-Macho
ACAngel Concheiro
Angel Concheiro

22 December 2009 in The Journal of Physical Chemistry C
Verified
Journal Article
Closed access
JGJaime Gonzalez-Lopez
Jaime Gonzalez-Lopez
ISIsabel Sandez-Macho
Isabel Sandez-Macho
ACAngel Concheiro
Angel Concheiro
Carmen Alvarez-LorenzoCarmen Alvarez-Lorenzo
Carmen Alvarez-Lorenzo

25 February 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MBManuel Busto-Iglesias
Manuel Busto-Iglesias
LMLorena Rodríguez Martínez
Lorena Rodríguez Martínez
CFCarmen Antía Rodríguez Fernández
Carmen Antía Rodríguez Fernández
JGJaime Gonzalez-Lopez
Jaime Gonzalez-Lopez
MGMiguel González-Barcia
Miguel González-Barcia
CMCristina Mondelo-García
Cristina Mondelo-García
Biological drugs, especially those targeting anti-tumour necrosis factor α (TNFα) molecule, have revolutionized the treatment of patients with non-infectious uveitis (NIU), a sight-threatening condition characterized by ocular inflammation that can lead to severe vision threatening and blindness. Adalimumab (ADA) and infliximab (IFX), the most widely used anti-TNFα drugs, have led to greater clinical benefits, but a significant fraction of patients with NIU do not respond to these drugs. The therapeutic outcome is closely related to systemic drug levels, which are influenced by several factors such as immunogenicity, concomitant treatment with immunomodulators, and genetic factors. Therapeutic drug monitoring (TDM) of drug and anti-drug antibody (ADAbs) levels is emerging as a resource to optimise biologic therapy by personalising treatment to bring and maintain drug concentration within the therapeutic range, especially in those patients where a clinical response is less than expected. Furthermore, some studies have described different genetic polymorphisms that may act as predictors of response to treatment with anti-TNFα agents in immune-mediated diseases and could be useful in personalising biologic treatment selection. This review is a compilation of the published evidence in NIU and in other immune-mediated diseases that support the usefulness of TDM and pharmacogenetics as a tool to guide clinicians’ treatment decisions leading to better clinical outcomes. In addition, findings from preclinical and clinical studies, assessing the safety and efficacy of intravitreal administration of anti-TNFα agents in NIU are discussed.

19 February 2020 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
JLJosé Lariño-Noia
José Lariño-Noia
DGDaniel De la Gglesia garcia
Daniel De la Gglesia garcia
JGJaime Gonzalez-Lopez
Jaime Gonzalez-Lopez
JDJavier Díaz-Lopez
Javier Díaz-Lopez
FMFernando Macías-García
Fernando Macías-García
JDJ. Enrique Domínguez-Muñoz
J. Enrique Domínguez-Muñoz